
Sunday, January 26, 2025 9:20:28 AM
made his long pick in the Robin Hood contest in Verona Pharma (VRNA). Verona's inhaled treatment for adults with chronic obstructive pulmonary disease (COPD) won FDA approval last June. On Jan. 8, it said fourth-quarter sales totaled $36 million in the multi-billion dollar blockbuster indication.
Recent VRNA News
- Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/15/2025 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 11:08:13 AM
- Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS • GlobeNewswire Inc. • 03/28/2025 11:00:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/18/2025 08:34:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/18/2025 08:22:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2025 12:15:16 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2025 08:23:23 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2025 09:31:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2025 01:46:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2025 11:07:16 AM
- Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/27/2025 11:00:00 AM
- Verona Pharma Announces March 2025 Investor Conference Participation • GlobeNewswire Inc. • 02/18/2025 11:00:00 AM
- Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/13/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2025 11:00:36 AM
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights • GlobeNewswire Inc. • 01/07/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 11:34:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/25/2024 09:42:08 PM
- Verona Pharma Announces December 2024 Investor Conference Participation • GlobeNewswire Inc. • 11/19/2024 07:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 02:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 11:56:12 PM
- Verona Pharma to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/05/2024 07:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2024 01:47:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 11:06:03 AM
- Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/04/2024 07:00:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM